Those in the D-VRd arm also received subcutaneous daratumumab at 1800 mg once weekly for cycles 1 and 2 and every 3 weeks for cycles 3 to 8. For cycles 9 and onward, patients in both arms received 25 ...

Nasdaq-listed American Depository Receipts (ADRs) of Genmab A/S (GMAB) rose over 1% on Thursday morning after Johnson & ...

Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Bio ...

Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net ...

Johnson & Johnson (J&J) has received approval from the European Commission (EC) for its subcutaneous (SC) Darzalex (daratumumab)-based quadruplet regimen in newly diagnosed multiple myeloma (MM).

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer ...

Turns out that even with all the research done over the years, plant seed formation still holds many secrets. Japan’s Nagoya University researchers have recently identified a completely new ...

patients given Darzalex (daratumumab)-subcutaneous (SC) therapy alongside bortezomib, lenalidomide and dexamethasone (VRd). These data, which were presented at the 6th European Myeloma Network (EMN) ...

Prehabilitation interventions prior to elective lumbar spine procedure may provide modest reductions in pain, disability, and health care costs, however, due to suboptimal certainty of evidence ...

The standard myeloma therapies patients received with teclistamab were either daratumumab (Darzalex) plus bortezomib, lenalidomide, and dexamethasone (Dara-VRd), or daratumumab plus lenalidomide and ...

Chaz Lucius, a 2021 first-round pick of the Winnipeg Jets, announced his retirement Tuesday as a result of a hereditary tissue disorder. Lucius played for the Jets' AHL affiliate, the Manitoba ...

"This approval means that newly diagnosed patients can receive daratumumab subcutaneous plus VRd and avoid the need for lengthy IV infusions." This approval follows the indication extension approval ...